

Birkhäuser Advances in Infectious Diseases

Jürgen Harder
Jens-M. Schröder
Editors

Antimicrobial Peptides

Role in Human Health and Disease

 Springer

Birkhäuser Advances in Infectious Diseases

Series editors

Stefan H. Kaufmann

Max Planck Institute for Infection Biology, Berlin, Germany

Andrew A. Mercer

Department of Microbiology and Immunology, University of Otago
Dunedin, New Zealand

Olaf Weber

Bonn, Germany

More information about this series at

<http://www.springer.com/series/5444>

Jürgen Harder • Jens-M. Schröder
Editors

Antimicrobial Peptides

Role in Human Health and Disease

 Springer

Editors

Jürgen Harder
Department of Dermatology
University-Hospital Schleswig-Holstein
Campus Kiel
Kiel
Germany

Jens-M. Schröder
Department of Dermatology
University-Hospital Schleswig-Holstein
Campus Kiel
Kiel
Germany

Birkhäuser Advances in Infectious Diseases

ISBN 978-3-319-24197-5

ISBN 978-3-319-24199-9 (eBook)

DOI 10.1007/978-3-319-24199-9

Library of Congress Control Number: 2015960250

Springer Cham Heidelberg New York Dordrecht London

© Springer International Publishing Switzerland 2016

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

Springer International Publishing AG Switzerland is part of Springer Science+Business Media
(www.springer.com)

Contents

1	Antimicrobial Peptides in Cutaneous Wound Healing	1
	Ole E. Sørensen	
2	Antimicrobial Peptides as Endogenous Antibacterials and Antivirals at the Ocular Surface	17
	Fabian Garreis, Martin Schicht, and Friedrich Paulsen	
3	Function of Antimicrobial Peptides in Lung Innate Immunity	33
	Frederik Seiler, Robert Bals, and Christoph Beisswenger	
4	Antimicrobial Peptides: Maintaining Sterility of the Urinary Tract	53
	Brian Becknell and John David Spencer	
5	Antimicrobial Peptides in the Gut	67
	Maureen J. Ostaff, Eduard F. Stange, and Jan Wehkamp	
6	Metal Sequestration: An Important Contribution of Antimicrobial Peptides to Nutritional Immunity	89
	Steven Damo and Thomas E. Kehl-Fie	
7	Regulation of Antimicrobial Peptide Gene Expression by Vitamin D	101
	Adrian F. Gombart	
8	Dichotomous Roles of Cationic Polypeptides Targeting HIV	115
	Alexander M. Cole and Amy Liese Cole	

9	Antimicrobial Peptides in Host Defense: Functions Beyond Antimicrobial Activity	129
	Kim Alan Brogden, Amber M. Bates, and Carol L. Fischer	
10	Antimicrobial Peptides: Do They Have a Future as Therapeutics?	147
	Michael Zasloff	
	Index	155

Chapter 1

Antimicrobial Peptides in Cutaneous Wound Healing

Ole E. Sørensen

Abstract Injury that breached the physical skin barrier increases the likelihood of infection. The wound healing process is divided into hemostasis, inflammation, proliferation, and tissue remodeling. Antimicrobial peptides play a major role for the antimicrobial defense at all these stages in wound healing, but the main sources of antimicrobial peptides vary with the different stages of wound healing coming from plasma proteins, neutrophils, and keratinocytes. Apart from being part of the antimicrobial defense, antimicrobial peptides play other important roles in wound healing as in angiogenesis, attraction of leukocytes, resolution of inflammation, and proliferation. Future studies will demonstrate whether antimicrobial peptides can be used therapeutically to improve the wound healing processes and reduce scar formation in chronic wounds.

1.1 Introduction

The intact skin constitutes a very efficient physical barrier toward surrounding microbes. Indeed, skin infections are rarely found in intact healthy skin. However, injury or wounding causes breach in the physical barrier of the skin increasing the likelihood of infections. Keeping the wound free of overt infection is a prerogative for successful wound healing (Edwards and Harding 2004). Indeed, chronic non-healing cutaneous wounds are most often infected with *Staphylococcus aureus* or *Pseudomonas aeruginosa* (Edwards and Harding 2004). Antimicrobial peptides (AMPs) play a major role for the antimicrobial defense during wound healing. Indeed, studies of the remarkable ability of the African frog *Xenopus laevis* to keep its wounds free of infections under non-sterile conditions led to the first identification of antimicrobial peptides (AMPs) from the skin (Zasloff 1987).

O.E. Sørensen

Nuclear Biology Laboratory, Division of Infection Medicine, BMC, B14, Department of Clinical Sciences, Lund University, Tornavägen 10, Lund SE-221 84, Sweden
e-mail: Ole_E.Sorensen@med.lu.se

Wound healing following injury is traditionally divided into four stages: (1) hemostasis, (2) inflammation, (3) proliferation, and (4) tissue remodeling (Singer and Clark 1999). AMPs are found at all stages of wound healing; however, the sources of AMPs are different at each of these stages of wound healing.

1.2 Generation of AMPs at the Different Stages of Wound Healing

1.2.1 Injury

Injury by itself leads to generation of AMPs. In frog skin, the injury-induced nervous stimulation leads to release of antimicrobial peptides from skin glands (Simmaco et al. 1998). Though similar mechanisms have not been described in mammals, injury does lead to activation of proteases that release membrane-bound growth factor like HB-EGF and amphiregulin that possess antimicrobial activity (Malmsten et al. 2007). Furthermore, these growth factors play a major role as inducers of the epidermal AMP expression at later stages in the wound healing process (Sørensen et al. 2006, 2008; Roupé et al. 2010). Surely, tissue injury may generate additional AMPs but a systematic study of antimicrobial peptides released by tissue injury is still to come.

1.2.2 Hemostasis

After injury, there is extravasation of plasma proteins into the wound with activation of complement and coagulation cascades. Activation of the complement system leads to generation of fragments of C3a with antimicrobial activity (Nordahl et al. 2004; Sonesson et al. 2007; Pasupuleti et al. 2007). The coagulation cascade is one of the principal host defenses in insects and activation of the human coagulation cascade leads to cleavage of several proteins like kininogen, fibrinogen, and thrombin involved in the coagulation cascade, which leads to generation of several antimicrobial peptides (Frick et al. 2006; Pålman et al. 2013; Papareddy et al. 2010). Thrombin knockout mice have increased susceptibility to infection with *Staphylococcus aureus* infection in their limited life span (Mullins et al. 2009), which may indicate an important role of the thrombin-derived AMPs.

1.2.3 Inflammation

After hemostasis follows influx of neutrophils followed by monocytes and lymphocytes to the wounds in the inflammatory stage of wound healing (Singer and Clark 1999). Neutrophils contain large amounts of antimicrobial peptides (Levy 1996;

Borregaard and Cowland 1997; Borregaard et al. 2007) important for the microbicidal activity of these cells (Flannagan et al. 2009). During the inflammatory phase, the major AMPs present in the wound will be derived from the neutrophils. The AMPs in neutrophils are found both in neutrophil granules and cytosol (Levy 1996; Borregaard and Cowland 1997). Neutrophils even produce an AMP like elafin after migration to the skin (Theilgaard-Mönch et al. 2004); however, the main antimicrobial peptides found in neutrophils are the α -defensins (HNPs) in azurophil granules (Ganz et al. 1985), cathelicidins in specific granules (Sørensen et al. 1997), and calgranulins (S100A8/S100A9) in the cytosol (Hessian et al. 1993).

The main antimicrobial activity of neutrophil defensins is exerted in the neutrophil phagolysosome (Joiner et al. 1989), but neutrophil defensins are also secreted to the exterior (Ganz 1987; Faurschou et al. 2002). Apart from their direct antibacterial and antiviral activity (Ganz et al. 1985; Daher et al. 1986), defensins also boost bacterial phagocytosis by macrophages (Soehnlein et al. 2008a). Neutrophil defensins have other functions of importance in wound healing. Human neutrophil defensins have chemotactic activity toward monocytes (Territo et al. 1989), T cells (Chertov et al. 1996), and immature dendritic cells (Yang et al. 2000a). Furthermore, these peptides are mitogenic for epithelial cells and fibroblasts (Murphy et al. 1993). Neutrophil defensins do not seem to have a nonredundant function in wound healing since mice neutrophils lack defensins (Eisenhauer and Lehrer 1992).

The cathelicidins present in specific granules (or large granules in rudiments) are stored as inactive proteins in the granules and the biological function is unleashed following extracellular cleavage with serine proteases from azurophil granules (Zanetti 2004). In porcine and bovine neutrophils, the cathelicidins are processed by elastase (Panyutich et al. 1997; Scocchi et al. 1992) while proteinase 3 is responsible for the processing of the human cathelicidin hCAP-18 to the antimicrobial peptide LL-37 (Sørensen et al. 2001), a peptide with broad-spectrum antimicrobial activity (Turner et al. 1998). The elastase-mediated processing porcine cathelicidins has been shown to be important for clearance of bacteria from wounds (Cole et al. 2001). Cathelicidins have other important functions in wound healing, both in the recruitment of mononuclear cells and in the tissue regeneration. It has long been recognized that neutrophils play a major role for the subsequent recruitment of monocytes (Ward 1968), and it has now been recognized that LL-37 plays a role for the recruitment of monocytes (Soehnlein et al. 2008b). Indeed, LL-37 has been shown to be a chemotactic factor toward monocytes as well as T cells and neutrophils (Yang et al. 2000b). Porcine and murine cathelicidins have importance for angiogenesis (Li et al. 2000; Koczulla et al. 2003) and both the porcine PR-39 and the human LL-37 induce expression of VEGF (Rodriguez-Martinez et al. 2008). Furthermore, treatment of wounds with the gene delivery of the human cathelicidin LL-37 promotes wound healing (Jacobsen et al. 2005; Steinstraesser et al. 2014; Carretero et al. 2008). Transactivation of the epidermal growth factor (EGFR) occurs in cutaneous wound healing (Tokumaru et al. 2000) and LL-37 has been shown to cause EGFR transactivation (Tjabringa et al. 2003) and thereby induce keratinocyte migration (Tokumaru et al. 2005). Furthermore, LL-37 suppresses both keratinocyte and neutrophil apoptosis (Chamorro et al. 2009; Nagaoka et al. 2006).

S100A8/S100A9 constitutes 40 % neutrophil cytosolic protein (Edgeworth et al. 1991) and is a potent antifungal agent (Steinbakk et al. 1990). In wounds, neutrophil-derived S100A8/S100A9 is probably released from dying neutrophils or from neutrophil extracellular traps (NETs) and contributes to killing of *Candida albicans* (Urban et al. 2009). Apart from the direct antifungal effect, S100A9 enhances microbicidal activity of neutrophils by enhancing phagocytosis (Simard et al. 2011) and S100A8/S100A9 is important for neutrophil accumulation in response to LPS (Vandal et al. 2003) and induces neutrophil chemotaxis and adhesion (Ryckman et al. 2003). S100A8/S100A9 mediates proinflammatory activities mediated by binding to TLR-4 (Vogl et al. 2007) or the receptor for advanced glycation end products (RAGE) (Hofmann et al. 1999). Additionally, calgranulins have functions that may limit tissue damage or are anti-inflammatory. S100A8/S100A9 is very sensitive to oxidation (Rafferty et al. 2001; Lim et al. 2008) and may, thus, act as oxidant scavenger. S100A8 induces expression of the anti-inflammatory cytokine IL-10 and protects against tissue injury (Hiroshima et al. 2014) and may, thus, play a role in resolution of inflammation.

1.2.4 Proliferative Phase

As the inflammatory cells recede from the wound, the epidermal keratinocytes become a major source for AMPs during the proliferative phase of wound healing. While non-injured epidermis contains constitutively expressed AMPs like hBD-1 and RNase 7, the expression of many AMPs is induced during wound healing and inflammation. Indeed, many AMPs like hBD-2, hBD-3, RNase 7, and psoriasin were originally isolated from inflamed epidermis (Gläser et al. 2005; Harder et al. 1997, 2001; Harder and Schröder 2002). Though some epidermal expression of the human cathelicidin hCAP-18/LL-37 may also be found in the inflammatory stage of wound healing (Dorschner et al. 2001), the peak expression of epidermal AMPs is found during the proliferative phase of wound healing (Roupé et al. 2010). The AMPs with increased epidermal expression during the proliferative phase of wound healing include hBD-2 (Schmid et al. 2001), hBD-3 (Sørensen et al. 2006), psoriasin (S100A7) (Lee and Eckert 2007), S100A8/S100A9 (Thorey et al. 2001), S100A15 (Roupé et al. 2010), elafin (vanBergen et al. 1996), SLPI (Schmid et al. 2001; Wogens et al. 1998), lactoferrin (Roupé et al. 2010), midkine (Frick et al. 2011), and NGAL (Sørensen et al. 2006). Since the various defensins arise from a common ancestral gene (Bevins et al. 1996), it is remarkable that neutrophils and keratinocytes share many of the same AMPs and antimicrobial proteins (see Table 1.1); however, the AMPs in keratinocytes are induced only during wound healing and inflammation while the AMPs in neutrophils are synthesized during normal neutrophil differentiation in the bone marrow (Borregaard et al. 2005). However, this means that the antimicrobial proteins and peptides are present in the wound over an extended time, though the cellular source varies.

Table 1.1 Antimicrobial peptides and proteins present in both neutrophils and keratinocytes

AMPs in neutrophils and keratinocytes	
Neutrophils	Keratinocytes
<i>Azurophil granules</i>	
α -defensins (HNP-1-4)	β -defensins (hBD-1-3)
Lysozyme	Lysozyme
<i>Specific and gelatinase granules</i>	
Lactoferrin, NGAL, hCAP-18/LL-37	Lactoferrin, NGAL, hCAP-18/LL-37
Transcobalamin, SLPI, lysozyme	Transcobalamin, SLPI, lysozyme
<i>Cytosol</i>	
Calgranulins (S100A8/S100A9)	Calgranulins (S100A8/S100A9)
<i>Produced following extravasation</i>	
Elafin	Elafin
	Keratinocyte AMPs not present in neutrophils
	Psoriasin, RNase7, S100A15

Since α - and β -defensins arise from an ancestral gene, it is remarkable how many other antimicrobial peptides and proteins found in keratinocytes are also found in neutrophils. See text for references

The expression of some AMPs during wound healing is dependent on inflammation, i.e., cytokines from infiltrating inflammatory cells as in the case of the IL-1-dependent hBD-2 expression (Liu et al. 2003; Sørensen et al. 2005). However, the expression of other AMPs, like hBD-3, is induced by the injury-induced EGFR activation in epidermal keratinocytes, even in the absence of inflammatory cells (Sørensen et al. 2006; Roupé et al. 2010), thus directly linking growth and tissue regeneration with AMP expression. Deficiency in the injury-induced hBD-3 expression has been linked to the severity of skin infections and nasal carriage of *S. aureus* (Zanger et al. 2010, 2011; Nurjadi et al. 2013). Additionally, many AMPs like S100A8/S100A9, SLPI, and NGAL are induced both by injury-induced GFR activation and proinflammatory cytokines (Roupé et al. 2010; Mork et al. 2003; Sørensen et al. 2003; Liang et al. 2006).

Though AMP expression mainly is induced during wound healing and inflammation, inflammatory stimuli seem to downregulate the expression of certain AMPs during wound healing. The antimicrobial chemokine CXCL14 is normally expressed in the epidermis (Maerki et al. 2009) but downregulated during wound healing and inflammation (Frick et al. 2011; Maerki et al. 2009). Likewise, RNase 7 protects healthy skin from *Staphylococcus aureus* infection (Simanski et al. 2010). The expression of RNase 7 is induced both by IFN- γ /IL-17 (Simanski et al. 2013) and significantly by EGFR activation in injured skin *ex vivo* (Wanke et al. 2011). Though RNase 7 is significantly induced through EGFR activation in injured skin *ex vivo*, the expression level of RNase 7 is the same in skin wounds *in vivo* as in non-injured skin (Roupé et al. 2010) indicating that some inflammatory mediators may downregulate the injury-induced RNase 7 expression.

The epidermal AMPs induced by wound healing generate a broad spectrum on antibacterial activity, e.g., hBD-3 against *S. aureus* and *S. pyogenes* (Harder et al. 2001), psoriasin against *E. coli* (Gläser et al. 2005), and calgranulins against *C. albicans* (Steinbakk et al. 1990). Though, for example, psoriasin has been implicated in defense against *E. coli* (Gläser et al. 2005) and hBD-3 and RNase 7 against *S. aureus* (Zanger et al. 2010; Simanski et al. 2010), the appearance of AMPs during the proliferative phase of wound healing raises the question of whether these peptides may play additional roles beyond antimicrobial defense of the wound. Notably, some AMPs seem to remain intracellular or cell associated while other AMPs are secreted. hBD-2 is readily secreted into the medium from multilayer epidermal keratinocyte cell cultures (Sørensen et al. 2005), while hBD-3 remains cell associated, both in multilayer epidermal keratinocytes cell cultures (Sørensen et al. 2005) and in whole epidermis (Sørensen et al. 2006). Though, the antimicrobial S100A proteins psoriasin (S100A7), calgranulins (S100A8/S100A9), and S100A15 are cytosolic, at least psoriasin is also found extracellularly (Gläser et al. 2005). For AMPs to interact with other cells, the AMPs must – at least partially – be found extracellularly.

Numerous cytokine-line functions have been attributed to hBD-2. hBD-2 activates dendritic cells through TLR-4 (Biragyn et al. 2002) and is a chemoattractant toward immature dendritic cells and memory T cells through CCR6 (Yang et al. 1999) and toward neutrophils, monocytes, and macrophages through CCR2 (Röhl et al. 2010). hBD-2 has been found to promote intestinal wound healing *in vitro* (Otte et al. 2008) and stimulate proliferation, migration, and cytokine production of epidermal keratinocytes (Niyonsaba et al. 2007).

Likewise, non-antimicrobial functions have been attributed to hBD-3 including chemoattractant properties (Röhl et al. 2010), antagonism of CXCR4 (Feng et al. 2006), and activation of mast cells with increase of vascular permeability (Chen et al. 2007). However, the fact that hBD-3 appears to remain cell associated in the skin (Sørensen et al. 2005 2006) questions whether these functions play a major role during wound healing.

The non-antimicrobial functions of psoriasin include chemotactic activity toward T lymphocytes and neutrophils (Jinquan et al. 1996) mediated by binding to RAGE (Wolf et al. 2008). This also promotes proliferation of endothelial cells (Shubbar et al. 2012). Psoriasin induces VEGF (Shubbar et al. 2012) and the expression of keratinocyte differentiation markers (Hattori et al. 2014) as well as strengthens the tight junction barrier in the skin (Hattori et al. 2014).

Though SLPI (secretory leukocyte protease inhibitor) is also found in neutrophils, keratinocytes are the major source of SLPI in wound healing (Jacobsen et al. 2008). SLPI is found to be secreted both in multilayer epidermal keratinocytes cell culture (Sørensen et al. 2003) and whole epidermis (Sørensen et al. 2006). SLPI has antimicrobial activity against bacteria (Hiemstra et al. 1996), fungi (Tomee et al. 1997), and HIV-1 (McNeely et al. 1995). During wound healing, the secreted SLPI has nonredundant functions (Ashcroft et al. 2000) by inhibiting the elastase-mediated cleavage the epithelial growth factor proepithelin to the growth-inhibitory epithelin (Zhu et al. 2002).

1.2.5 Tissue Remodeling Phase

Tissue remodeling in cutaneous wound healing involves increased expression of collagen VI (Betz et al. 1993) that has antimicrobial activity (Abdillahi et al. 2012). Interestingly, collagen VI expression in fibroblasts is induced by neutrophil defensins (Li et al. 2006). The regulation of expression of antimicrobial proteins and peptides in the underlying connective tissue of skin will likely receive more interest after the finding that the normal skin microbiome extends to the connective tissue (Nakatsuji et al. 2013).

1.2.6 Chronic Wounds

Though many studies demonstrate how microbial products induce AMP expression in keratinocytes mainly through TLR activation (Abtin et al. 2008; Büchau et al. 2007, 2008; Li et al. 2013; Nagy et al. 2005; Gariboldi et al. 2008; Gerstel et al. 2009; Liu et al. 2002), the possible significance of this in acute wound healing in noninfected wounds is not clear. The bacteria-induced AMP expression may be more important in chronic wounds with infections (Edwards and Harding 2004). Furthermore, in this instance, the bacterial proteases could play contradictory roles, either by induction of AMP expression through protease-activated receptors (Chung et al. 2004) or by AMP degradation (Schmidtchen et al. 2002). Chronic wounds like chronic venous ulcers are characterized by chronic inflammation with continuous recruitment of inflammatory cells, and indeed neutrophil AMPs like neutrophils defensins are found in high amounts (Lundqvist et al. 2008). The epidermal expression of hBD-2 and psoriasin is induced in chronic venous ulcers (Butmarc et al. 2004; Dressel et al. 2010), while the expression of LL-37 is decreased (Heilborn et al. 2003). In diabetic wounds, the high glucose levels may suppress the expression of both hBD-2 (Lan et al. 2012) and hBD-3 (Lan et al. 2011) in keratinocytes. To understand the role of AMPs in chronic wound pathology or chronic wound infections, more detailed studies are needed to delineate the AMP expression in different types of chronic wounds and how this is related to wound infection or underlying disease such as diabetes.

1.3 Concluding Remarks and Future Perspective

AMPs provide part of the antimicrobial defense during wound healing. Topical application of antimicrobials do not improve normal wound healing (Lipsky and Hoey 2009), demonstrating adequate antimicrobial defenses. While the AMPs originating from the coagulation and complement cascades, the neutrophils, and epidermal keratinocytes undoubtedly contribute to the antimicrobial defense in the

wound healing process, it is difficult to decipher the role of individual AMPs due to overlapping antimicrobial activities. Apart from SLPI (Ashcroft et al. 2000), no AMP has been demonstrated to possess nonredundant functions during wound healing.

Though mice models provide useful insight, it is important to note that differences exist between humans and mice – also when it comes to both wound healing and AMPs. Wound contractions are important for wound healing in rodents such as mice, but not in humans (Davidson 1998). Neutrophils and keratinocytes are major sources of AMPs during wound healing, but mice have far fewer neutrophils than humans (Mestas and Hughes 2004) and the mouse epidermis contains far fewer keratinocytes than human epidermis. Accordingly, though no directly comparative studies exist, it seems reasonable that the mouse wounds will contain fewer AMPs than human wounds. There will also be qualitative difference in the AMPs. The mouse contains many more different β -defensins than humans (Schutte et al. 2002), while there will be no neutrophil α -defensins in mouse wounds (Eisenhauer and Lehrer 1992). The neutrophil α -defensins play a role for the antimicrobial function of the neutrophils (Sørensen et al. 2014), and this will undoubtedly be important for the antimicrobial defense also in wounds.

While even infected wounds only in some instances benefit from topical treatment with antibiotics (Lipsky and Hoey 2009), gene delivery of AMPs has been found to have beneficial effects for wound healing (Jacobsen et al. 2005; Steinstraesser et al. 2014; Carretero et al. 2008). This clearly indicates that AMPs have beneficial effects in wound healing beyond its antimicrobial properties. AMPs are generated at all stages of wound healing and it does seem like AMPs participate in the regulation of some aspects of the wound healing processes, for instance, LL-37 plays a role for recruitment of monocytes (Soehnlein et al. 2008b). Resolution of inflammation is now recognized as a regulated process (Serhan and Savill 2005; Ortega-Gomez et al. 2013), and in wounds, AMPs may play an important role here. Dying and necrotic neutrophils are anti-inflammatory due to the release of neutrophil defensins (Miles et al. 2009) and calgranulin S100A8, which induce the anti-inflammatory cytokine IL-10. Later, IL-10 may play a role for downregulation of AMP expression in keratinocytes (Howell et al. 2005). Both defensins and LL-37 promote proliferation of keratinocytes (Niyonsaba et al. 2007; Heilborn et al. 2003). Accordingly, AMPs may play a role for inflammation, resolution of inflammation, and proliferation during wound healing. One of the paradoxes of psoriasis, a disease with very prominent AMP expression (Harder and Schröder 2005), is the lack of scarring following the chronic inflammation (Nickoloff et al. 2006). Future studies will further address the role of AMPs for regulation of the wound healing process and scar formation. This will hopefully pave the way for new treatment modalities for chronic wounds and wound infection.

Acknowledgments This work was supported by grants from the Alfred Österlunds Stiftelse, the Royal Physiografic Society Lund, Greta och Johan Kocks Stiftelse, Petrus och Augusta Hedlunds Stiftelse, and the Swedish Research Council.

References

- Abdillahi SM, Balvanovic S, Baumgarten M, Mörgelin M (2012) Collagen VI encodes antimicrobial activity: novel innate host defense properties of the extracellular matrix. *J Innate Immun* 4:371–376
- Abtin A, Eckhart L, Mildner M, Gruber F, Schröder JM, Tschachler E (2008) Flagellin is the principal inducer of the antimicrobial peptide S100A7c (psoriasin) in human epidermal keratinocytes exposed to *Escherichia coli*. *FASEB J* 22:2168–2176
- Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB, Greenwell-Wild T, Hale-Donze H, McGrady G, Song XY, Wahl SM (2000) Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. *Nat Med* 6:1147–1153
- Betz P, Nerlich A, Wilske J, Tubel J, Penning R, Eisenmenger W (1993) Immunohistochemical localization of collagen types I and VI in human skin wounds. *Int J Legal Med* 106:31–34
- Bevins CL, Jones DE, Dutra A, Schaffzin J, Muenke M (1996) Human enteric defensin genes: chromosomal map position and a model for possible evolutionary relationships. *Genomics* 31:95–106
- Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ et al (2002) Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. *Science* 298:1025–1029
- Borregaard N, Cowland JB (1997) Granules of the human neutrophilic polymorphonuclear leukocyte. *Blood* 89:3503–3521
- Borregaard N, Theilgaard-Monch K, Cowland JB, Stahle M, Sørensen OE (2005) Neutrophils and keratinocytes in innate immunity – cooperative actions to provide antimicrobial defense at the right time and place. *J Leukoc Biol* 77:439–443
- Borregaard N, Sørensen OE, Theilgaard-Mönch K (2007) Neutrophil granules: a library of innate immunity proteins. *Trends Immunol* 28:340–345
- Büchau AS, Hassan M, Kukova G, Lewerenz V, Kellermann S, Würthner JU, Wolf R, Walz M, Gallo RL, Ruzicka T (2007) S100A15, an antimicrobial protein of the skin: regulation by *E-coli* through toll-like receptor 4. *J Invest Dermatol* 127:2596–2604
- Büchau AS, Schaubert J, Hultsch T, Stuetz A, Gallo RL (2008) Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. *J Invest Dermatol* 128:2646–2654
- Butmarc J, Yufit T, Carson P, Falanga V (2004) Human beta-defensin-2 expression is increased in chronic wounds. *Wound Repair Regen* 12:439–443
- Carretero M, Escamez MJ, Garcia M, Duarte B, Holguin A, Retamosa L, Jorcano JL, Rio MD, Larcher F (2008) In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. *J Invest Dermatol* 128:223–236
- Chamorro CI, Weber G, Gronberg A, Pivarcsi A, Stahle M (2009) The human antimicrobial peptide LL-37 suppresses apoptosis in keratinocytes. *J Invest Dermatol* 129:937–944
- Chen X, Niyonsaba F, Ushio H, Hara M, Yokoi H, Matsumoto K, Saito H, Nagaoka I, Ikeda S, Okumura K et al (2007) Antimicrobial peptides human beta-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability. *Eur J Immunol* 37:434–444
- Chertov O, Michiel DF, Xu L, Wang JM, Tani K, Murphy WJ, Longo DL, Taub DD, Oppenheim JJ (1996) Identification of defensin-1, defensin-2, and CAP37/azurocidin as T- cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. *J Biol Chem* 271:2935–2940
- Chung WO, Hansen SR, Rao D, Dale BA (2004) Protease-activated receptor signaling increases epithelial antimicrobial peptide expression. *J Immunol* 173:5165–5170
- Cole AM, Shi J, Ceccarelli A, Kim YH, Park A, Ganz T (2001) Inhibition of neutrophil elastase prevents cathelicidin activation and impairs clearance of bacteria from wounds. *Blood* 97:297–304
- Daher KA, Selsted ME, Lehrer RI (1986) Direct inactivation of viruses by human granulocyte defensins. *J Virol* 60:1068–1074

- Davidson JM (1998) Animal models for wound repair. *Arch Dermatol Res* 290(Suppl):S1–S11
- Dorschner RA, Pestonjamas VK, Tamakuwala S, Ohtake T, Rudisill J, Nizet V, Agerberth B, Gudmundsson GH, Gallo RL (2001) Cutaneous injury induces the release of cathelicidin antimicrobial peptides active against group A *Streptococcus*. *J Invest Dermatol* 117:91–97
- Dressel S, Harder J, Cordes J, Wittersheim M, Meyer-Hoffert U, Sunderkotter C, Glaser R (2010) Differential expression of antimicrobial peptides in margins of chronic wounds. *Exp Dermatol* 19:628–632
- Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N (1991) Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. *J Biol Chem* 266:7706–7713
- Edwards R, Harding KG (2004) Bacteria and wound healing. *Curr Opin Infect Dis* 17:91–96
- Eisenhauer PB, Lehrer RI (1992) Mouse neutrophils lack defensins. *Infect Immun* 60:3446–3447
- Faurschou M, Sørensen OE, Johnsen AH, Askaa J, Borregaard N (2002) Defensin-rich granules of human neutrophils: characterization of secretory properties. *Biochim Biophys Acta* 1591:29–35
- Feng Z, Dubyak GR, Lederman MM, Weinberg A (2006) Cutting edge: human beta defensin 3 – a novel antagonist of the HIV-1 coreceptor CXCR4. *J Immunol* 177:782–786
- Flannagan RS, Cosio G, Grinstein S (2009) Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. *Nat Rev Microbiol* 7:355–366
- Frick IM, Åkesson P, Herwald H, Mörgelin M, Malmsten M, Nagler DK, Björck L (2006) The contact system – a novel branch of innate immunity generating antibacterial peptides. *EMBO J* 25:5569–5578
- Frick IM, Nordin SL, Baumgarten M, Mörgelin M, Sørensen OE, Olin AI, Egesten A (2011) Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal *Finlayella magna* and the pathogen *Streptococcus pyogenes*. *J Immunol* 187:4300–4309
- Ganz T (1987) Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes. *Infect Immun* 55:568–571
- Ganz T, Selsted ME, Szklarek D, Harwig SSL, Daher K, Bainton DF, Lehrer RI (1985) Defensins. Natural peptide antibiotics of human neutrophils. *J Clin Invest* 6:1427–1435
- Gariboldi S, Palazzo M, Zanobbio L, Sella S, Sommariva M, Sfondrini L, Cavicchini S, Balsari A, Rumio C (2008) Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of beta-defensin 2 via TLR2 and TLR4. *J Immunol* 181:2103–2110
- Gerstel U, Czapp M, Bartels J, Schröder JM (2009) Rhamnolipid-induced shedding of flagellin from *Pseudomonas aeruginosa* provokes hBD-2 and IL-8 response in human keratinocytes. *Cell Microbiol* 11:842–853
- Glaser R, Harder J, Lange H, Bartels J, Christophers E, Schröder JM (2005) Antimicrobial psoriasin (S100A7) protects human skin from *Escherichia coli* infection. *Nat Immunol* 6:57–64
- Harder J, Schröder JM (2002) RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin. *J Biol Chem* 277:46779–46784
- Harder J, Schröder JM (2005) Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. *J Leukoc Biol* 77:476–486
- Harder J, Bartels J, Christophers E, Schröder JM (1997) A peptide antibiotic from human skin. *Nature* 387:861
- Harder J, Bartels J, Christophers E, Schröder JM (2001) Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. *J Biol Chem* 276:5707–5713
- Hattori F, Kiatsurayanon C, Okumura K, Ogawa H, Ikeda S, Okamoto K, Niyonsaba F (2014) The antimicrobial protein S100A7/psoriasin enhances the expression of keratinocyte differentiation markers and strengthens the skin's tight junction barrier. *Br J Dermatol* 171:742–753
- Heilborn JD, Nilsson MF, Kratz G, Weber G, Sørensen O, Borregaard N, Stahle-Backdahl M (2003) The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. *J Invest Dermatol* 120:379–389